Digital-twin model identifies two candidate drugs for delaying preterm labor

A computational “digital twin” model identified two of nine FDA-approved, low-risk drugs as potential candidates for delaying the onset of preterm labor, according to a peer-reviewed study in Science Advances. The framework, called Simulated Immunome Modeling of Clinical Outcomes, or SIMCO, modeled how nine medicines affected immune-cell activity associated with labor. A form of folic acid and a combination of salicylic acid with lansoprazole emerged as the strongest candidates, but the results do not demonstrate that either treatment can prevent preterm birth in patients.

Jakob Einhaus and colleagues first tested the drugs on immune cells from blood samples donated by pregnant and non-pregnant people. The nine interventions were chlorthalidone, maprotiline, metformin, lansoprazole, pravastatin, rifabutin, salicylic acid, salicylic acid plus lansoprazole, and 5-methyltetrahydrofolate, a form of folic acid. The researchers established the effects of these treatments on the cells in vitro, then combined those results with a second set of untreated samples to relate molecular immune activity to gestational age at delivery. That second dataset included samples from 11 pregnant participants, while eight non-pregnant people served as controls.

By integrating the two experiments, the researchers constructed SIMCO’s digital twins to replicate how the drugs altered labor-related immune-cell activity. Under the model, tetrahydrofolate and the salicylic-acid-plus-lansoprazole combination had the greatest potential to delay labor onset. The other seven drugs initially produced a counterproductive response in the model, appearing to speed labor-related changes before slowing them. These findings are computational estimates based on laboratory observations and a small donor dataset; they are not clinical-trial outcomes, and the study did not establish that the candidate drugs would delay delivery when administered during pregnancy.

The work was presented as a possible response to the limited number of prenatal interventions available for pregnancy complications. According to the research summary, trials in this area face ethical difficulties, restrictive regulations and underfunding. A related Focus noted that the therapeutic gap reflects scientific challenges as well as a history of tragic failures in treating pregnant people. SIMCO offers a way to evaluate how existing drugs might affect labor-associated immune activity using experimental and human sample data. Its shortlist may help direct further investigation, but the published evidence remains a modeling study rather than proof of clinical benefit.

Subject of Research: Digital-twin screening of approved drugs for potential preterm-labor prevention

Article Title: Two out of nine FDA-approved drugs could slow preterm labor, new digital twin model suggests

Article References: Two out of nine FDA-approved drugs could slow preterm labor, new digital twin model suggests. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: preterm labor, digital twins, SIMCO, drug screening, immune cells, pregnancy, folic acid, aspirin, lansoprazole, single-cell modeling, nine, FDA-approved